0
Summaries for Patients |

The Blood Pressure Drug Losartan Appears To Benefit the Kidneys of People with Type 2 Diabetes Who Do Not Have High Blood Pressure FREE

[+] Article and Author Information

The summary below is from the full report titled “Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus. A Randomized Clinical Trial.” It is in the 15 July 2003 issue of Annals of Internal Medicine (volume 139, pages 90-96). The authors are A.A.M. Zandbergen, M.G.A. Baggen, S.W.J. Lamberts, A.H. Bootsma, D. de Zeeuw, and R.J.Th. Ouwendijk.


Ann Intern Med. 2003;139(2):I-24. doi:10.7326/0003-4819-139-2-200307150-00002
Text Size: A A A

What is the problem and what is known about it so far?

Type 2 diabetes mellitus interferes with the body's ability to use insulin, a substance created by the pancreas to store energy from food. In people with type 2 diabetes, the body makes plenty of insulin but can't use it normally. The result is high blood sugar levels. Over time, high blood sugar can lead to complications, including kidney problems. Diabetes is the most common cause of kidney failure in the United States. Good control of blood sugar and blood pressure delays the development of kidney problems in people with type 2 diabetes. Blood pressure drugs called angiotensin-converting enzyme inhibitors also protect people with type 2 diabetes against kidney problems. This benefit occurs whether or not people also have high blood pressure. Another type of blood pressure drug called angiotensin-receptor antagonists (AR antagonists) protects against kidney problems in people who have both type 2 diabetes and high blood pressure. However, we don't know if AR antagonists protect the kidneys in people with type 2 diabetes and normal blood pressure.

Why did the researchers do this particular study?

To see whether AR antagonists protect the kidneys of people with type 2 diabetes and normal blood pressure.

Who was studied?

149 patients from medical centers in the Netherlands who had type 2 diabetes, had a blood pressure of 150/90 mm Hg or less, and were not receiving any blood pressure drugs. All the patients had microalbuminuria, an early sign of kidney disease in which the kidneys leak small amounts of the protein albumin into the urine.

How was the study done?

The researchers assigned patients at random to take either the AR antagonist losartan or a placebo pill. The placebo pill was similar to losartan but contained no active ingredients. Using blood and urine tests, the researchers measured the amount of albumin that leaked into urine after 5 and 10 weeks. More albumin indicates worse kidney function.

What did the researchers find?

At both 5 and 10 weeks, patients receiving losartan had more favorable changes in albumin measurements than did patients receiving placebo.

What were the limitations of the study?

Albumin is only a rough laboratory test for how well the kidneys are working. The study was too small and too short to show any differences in the development of kidney disease.

What are the implications of the study?

Angiotensin-receptor antagonists such as losartan deserve further study as a way to protect against kidney disease in patients with type 2 diabetes and normal blood pressure.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)